Condition: Growth Hormone Deficiency (GHD) · Sponsor: Lumos Pharma
The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201.
This description comes directly from the study's public registry record.
Lumos Pharma · 515-598-2921 · clinical.trials@lumos-pharma.com
Always discuss trial participation with your own doctor first.
| Lumos Pharma Investigational Site | Birmingham, Alabama, United States | Recruiting |
| Lumos Pharma Investigational Site | Madera, California, United States | Recruiting |
| Lumos Pharma Investigational Site | Orange, California, United States | Recruiting |
| Lumos Pharma Investigational Site | Sacramento, California, United States | Recruiting |
| Lumos Pharma Investigational Site | San Diego, California, United States | Recruiting |
| Lumos Pharma Investigational Site | Centennial, Colorado, United States | Recruiting |
| Lumos Pharma Investigational Site | Greenwood Village, Colorado, United States | Recruiting |
| Lumos Pharma Investigational Site | Washington D.C., District of Columbia, United States | Recruiting |
| Lumos Pharma Investigational Site | Hollywood, Florida, United States | Recruiting |
| Lumos Pharma Investigational Site | Miami, Florida, United States | Recruiting |
| Lumos Pharma Investigational Site | Orlando, Florida, United States | Recruiting |
| Lumos Pharma Investigational Site | Tallahassee, Florida, United States | Recruiting |
+ 31 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06948214